IJH vs XBI
iShares Core S&P Mid-Cap ETF vs SPDR S&P Biotech ETF
- • IJH has the lower expense ratio at 0.05% vs 0.35% for XBI.
- • IJH pays a higher dividend yield (1.23%).
Side-by-side metrics
| Metric | IJH | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.05% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.23% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $123.20B | $10.92B |
YTD return | 13.60% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.99 | 1.01 |
P/E ratio | 19.23 | — |
Last price | $74.78 | $156.41 |
Inception | — | — |
Issuer | iShares | State Street |
IJH top holdings
| OKTA | Okta Inc Class A | 1.01% |
| FTI | TechnipFMC PLC | 0.79% |
| UTHR | United Therapeutics Corp | 0.75% |
| ENTG | Entegris Inc | 0.69% |
| ATI | ATI Inc | 0.66% |
| USFD | US Foods Holding Corp | 0.65% |
| RS | Reliance Inc | 0.65% |
| XPO | XPO Inc | 0.65% |
| THC | Tenet Healthcare Corp | 0.64% |
| PR | Permian Resources Corp Class A | 0.64% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About IJH
IJH (iShares Core S&P Mid-Cap ETF) is Tracks the S&P MidCap 400 index. Managed by iShares, the fund carries $123.2B in assets under management, an expense ratio of 0.05%, a dividend yield of 1.23%. Its largest holding is Okta Inc Class A (OKTA), which represents 1.0% of the portfolio. Real Estate is the fund's largest sector exposure at 8.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.